{"product_id":"trvi-marketing-mix","title":"(TRVI) Trevi Therapeutics, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Trevi Therapeutics, Inc. 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategy and explains what the product is and how it’s used; the page includes a real preview\/sample so you can assess style and content before buying. Purchase the full version to get the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaduvio oral ER nalbuphine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaduvio is Trevi Therapeutics, Inc.'s lead asset, an oral extended-release nalbuphine designed to control severe, neurologically driven symptoms with an opioid-modulating, not classic opioid, mechanism. It is built for chronic cough and other hard-to-treat conditions where symptom relief matters fast. In Trevi Therapeutics, Inc.'s 4P mix, this is the core Product and the main value driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase IIb\/III chronic pruritus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrevi Therapeutics, Inc. is advancing Haduvio for chronic pruritus in Phase IIb\/III, targeting a severe itching burden with few approved options. Chronic pruritus affects about 8-14% of adults overall, and rates can exceed 60% in some liver or kidney disease groups. Trevi is positioning Haduvio as a specialty therapy for this unmet need, where durable itch relief can be a key value driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase IIb\/III persistent cough in IPF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrevi Therapeutics’ Haduvio is being studied in Phase IIb\/III for persistent cough in idiopathic pulmonary fibrosis (IPF), a chronic cough with no approved treatment. IPF is a rare, progressive lung disease, and cough can be severe, frequent, and hard to control. This gives Trevi a second lead rare-pulmonary indication alongside its core cough program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNalbuphine hydrochloride rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrevi Therapeutics, Inc.'s nalbuphine hydrochloride rights rest on a licensing deal with Endo Pharmaceuticals Inc., which gives Trevi the IP base to develop and market nalbuphine-based formulations. That license is central to the Company’s product strategy because it supports Haduvio and other nalbuphine programs, with 2025 filings showing the asset remains the core of Trevi’s pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing deal secures nalbuphine IP\u003c\/li\u003e\n\u003cli\u003eSupports formulation development and marketing\u003c\/li\u003e\n\u003cli\u003eCore foundation for Trevi’s product mix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical-stage pipeline only\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs of July 2026, Trevi Therapeutics, Inc. remains a clinical-stage biopharmaceutical company with no approved products and no commercial product revenue. Its product value sits on trial data, not sales, so each efficacy or safety update can move the stock fast.\u003c\/p\u003e\n\u003cp\u003eThe lead asset, Haduvio, is in late-stage development for chronic cough tied to idiopathic pulmonary fibrosis and refractory chronic cough, making trial execution the core of product strategy. Success means regulatory optionality; failure means the pipeline stays pre-revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo approved products\u003c\/li\u003e\n\u003cli\u003eValue tied to milestones\u003c\/li\u003e\n\u003cli\u003eLead asset is Haduvio\u003c\/li\u003e\n\u003cli\u003eTrial results drive re-rating\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrevi’s Value Hinges on Haduvio Clinical Progress\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrevi Therapeutics, Inc.'s product mix is built almost entirely on Haduvio, an oral extended-release nalbuphine for chronic cough and pruritus. As of 2026, Trevi Therapeutics, Inc. has no approved products and no commercial product revenue, so value depends on clinical data and regulatory progress. Its late-stage programs in refractory chronic cough and IPF cough are the main product drivers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey product\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eValue driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHaduvio\u003c\/td\u003e\n\u003ctd\u003ePhase IIb\/III\u003c\/td\u003e\n\u003ctd\u003eClinical readouts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrevi Therapeutics, Inc.\u003c\/td\u003e\n\u003ctd\u003eNo approved products\u003c\/td\u003e\n\u003ctd\u003eNo product revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific breakdown of Trevi Therapeutics, Inc.’s Product, Price, Place, and Promotion strategy, grounded in real market context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSummarizes Trevi Therapeutics’ 4Ps as a clear pain-relief marketing snapshot for quick strategy review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources that link each key claim about Trevi Therapeutics to traceable industry reports, regulatory filings, and clinical data for fast, defensible due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Haven, Connecticut HQ\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrevi Therapeutics, Inc. is headquartered in New Haven, Connecticut, and that site serves as its corporate and operating base. New Haven had 134,023 residents in the 2020 Census, giving Trevi Therapeutics access to a dense Northeast biotech and talent pool for management, development oversight, and partnership work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrev Therapeutics, Inc. distributes Haduvio only through clinical research sites, so the current place is investigator-led studies and specialty trial centers. Access stays tightly limited to enrolled patients in ongoing trials, which keeps the drug out of normal pharmacy channels. As a pre-commercial company, Trevi still has no Haduvio product sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist physician centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialist physician centers are Trevi Therapeutics, Inc.'s key place channel because chronic pruritus and IPF cough are treated by pulmonologists and dermatology-focused specialists, not mass retail. IPF affects roughly 100,000-200,000 people in the U.S., so access depends on referral-driven specialty care. That makes high-trust specialty clinics the main route for diagnosis, prescribing, and follow-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture specialty pharmacy channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf approved, Haduvio would likely be dispensed through a specialty pharmacy, which is standard for high-touch therapies that need prior authorization, tight inventory control, and patient onboarding. This channel can also bundle refill checks, side-effect monitoring, and copay support, which helps keep start-up friction lower for complex chronic care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eControlled dispensing\u003c\/li\u003e\n\u003cli\u003ePrior authorization support\u003c\/li\u003e\n\u003cli\u003ePatient services and refill follow-up\u003c\/li\u003e\n\u003cli\u003eBest fit for complex therapies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo commercial market access yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrevi Therapeutics has no commercial sales or broad distribution network for Haduvio yet, so its place strategy is still pre-launch and trial-based. The latest reported product revenue remains $0, which fits a pre-commercial model. Market access, payer coverage, and channel build-out would only come after regulatory success.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0 commercial reach today\u003c\/li\u003e\n\u003cli\u003eTrial-site driven access only\u003c\/li\u003e\n\u003cli\u003ePost-approval market access next\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaduvio Stays in Clinical Channels, Not Retail\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrevi Therapeutics, Inc. keeps Place tightly controlled: Haduvio is still limited to clinical trial sites and specialty centers, not retail pharmacies. With no commercial sales and product revenue at $0, its U.S. access route remains investigator-led and referral-based. If approved, specialty pharmacy would likely become the main channel for prior auth and patient support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent channel\u003c\/td\u003e\n\u003ctd\u003eClinical trial sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial reach\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLikely post-approval\u003c\/td\u003e\n\u003ctd\u003eSpecialty pharmacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTrevi Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Trevi Therapeutics 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase IIb\/III data readouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor Trevi Therapeutics, Inc., Phase IIb\/III readouts are the core promotional asset because the company is still clinical-stage and has no marketed product. These data show efficacy, safety, and how Haduvio can stand out in cough and itch settings, where even small shifts in endpoints can move investor and physician interest. In practice, one strong readout can do more than any ad spend: it gives the company its main proof point.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical congress presentations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrevi Therapeutics can use medical congress presentations to put Haduvio data in front of specialists, researchers, and potential clinical partners. Poster and oral sessions help explain the drug’s mechanism and clinical results, which builds trust faster than broad ads for a niche therapy. For a program that still needs deeper physician awareness, peer-reviewed visibility at major meetings can carry more weight than paid promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor relations updates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrevi Therapeutics uses earnings calls, press releases, and SEC filings to keep investors updated on Haduvio trial progress, milestones, and cash runway. In its latest reported quarter, the Company said it had about $149 million in cash and cash equivalents, which helps frame funding through key readouts. For a public biotech, this investor news flow is a core promotion tool because it shapes trust and trading interest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial recruitment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrevi Therapeutics, Inc. uses clinical trial recruitment to drive enrollment in its Phase IIb\/III studies, reaching investigators and eligible patients through research networks. In its 2025 reporting, the company kept a lean structure, with R\u0026amp;D spend focused on advancing Haduvio and trial execution rather than broad consumer promotion. Faster site activation and patient outreach can cut enrollment delays, which often add months to timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets investigators and eligible patients\u003c\/li\u003e\n\u003cli\u003eUses research networks for outreach\u003c\/li\u003e\n\u003cli\u003eSupports Phase IIb\/III enrollment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnering and licensing outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrevi Therapeutics, Inc. uses business development outreach to support partnering and licensing around Haduvio (nalbuphine ER). The Endo license adds credibility because it links the program to an established opioid-therapy platform, and Trevi can use that in talks with regulators and commercialization partners. As of the latest filings, Trevi still has no product revenue, so partner-led promotion remains key.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilds licensing credibility\u003c\/li\u003e\n\u003cli\u003eSupports regulatory talks\u003c\/li\u003e\n\u003cli\u003ePrepares commercialization deals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrevi Therapeutics Bets on Clinical Proof and Cash Runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrevi Therapeutics’ promotion is mainly clinical proof and investor messaging: Haduvio data from Phase IIb\/III readouts, congress talks, and SEC updates drive awareness because the Company has no product revenue. In the latest quarter, cash and cash equivalents were about $149 million, supporting trial promotion and enrollment through 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePromotion channel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical readouts\u003c\/td\u003e\n\u003ctd\u003eMain proof point\u003c\/td\u003e\n\u003ctd\u003ePhase IIb\/III\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestor updates\u003c\/td\u003e\n\u003ctd\u003eBuild trust\u003c\/td\u003e\n\u003ctd\u003e$149M cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCongress\/partner outreach\u003c\/td\u003e\n\u003ctd\u003eBoost visibility\u003c\/td\u003e\n\u003ctd\u003eNo product revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo approved list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaduvio has no approved commercial list price as of July 2026 because Trevi Therapeutics remains in clinical development. The drug is still not FDA-approved, so any list price would only be set after regulatory approval and launch. Trevi reported cash, cash equivalents, and marketable securities of $287.8 million at Q1 2026, underscoring that pricing is still a future event.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo routine payer reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrevi Therapeutics, Inc. has no routine payer reimbursement today because its product is not yet marketed, so there is no standard coverage pathway. Any future coverage will hinge on label breadth, phase 3 data, and health economics, which matters most for specialty and rare-disease drugs where payers often demand prior authorization and step edits. In the U.S., specialty drugs already account for over 50% of total drug spending, so reimbursement risk is material.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty-drug pricing model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf approved, Haduvio would likely use a specialty-drug price model, since specialty medicines are only about 2% of U.S. prescriptions but drive roughly 50% to 55% of drug spend. Pricing would need to cover a small patient pool, high R\u0026amp;D cost, and the value of chronic symptom relief, so access and payer rebates would matter as much as list price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eValue-based access strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrevi Therapeutics, Inc. should use a value-based access strategy: tie reimbursement to measured outcomes and the clear unmet need in chronic cough. With no product revenue in 2025, access terms must win specialty-care adoption through prior-authorization support and patient services, not price alone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOutcomes-linked reimbursement\u003c\/li\u003e\n\u003cli\u003ePrior-authorization help\u003c\/li\u003e\n\u003cli\u003ePatient support services\u003c\/li\u003e\n\u003cli\u003eSpecialty-care adoption focus\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo retail discount structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrevi Therapeutics, Inc. has no consumer retail pricing model today, because it is not selling through mass-market channels. Pricing for Haduvio will be set after FDA approval, through prescription-only use, payer negotiations, and launch planning. That means no retail discount structure exists yet, just future access and reimbursement strategy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrescription-only pricing, not retail pricing\u003c\/li\u003e\n\u003cli\u003eNo mass-market channel today\u003c\/li\u003e\n\u003cli\u003ePayer rebates will shape net price\u003c\/li\u003e\n\u003cli\u003eLaunch timing will set the model\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaduvio Still Lacks a List Price as Trevi Prepares for Launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaduvio still has no approved list price in July 2026, so Trevi Therapeutics, Inc. has not set a commercial price or rebate base yet. With no product revenue in 2025 and $287.8 million in cash, cash equivalents, and marketable securities at Q1 2026, pricing remains a launch-stage issue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice signal\u003c\/th\u003e\n\u003cth\u003e2026\/2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved price\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003eNone in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash at Q1 2026\u003c\/td\u003e\n\u003ctd\u003e$287.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235022577929,"sku":"trvi-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/trvi-marketing-mix.webp?v=1785734135","url":"https:\/\/dcfanalyst.com\/products\/trvi-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}